Gland Pharma Limited, a generic injectable-focused pharmaceutical company, announced its financial results for the first quarter ended on 30th June 2025.

The company reported consolidated net profit rose nearly 50% for the June quarter to Rs.215.5 crore from Rs.143.8 crore a year earlier as revenue from all but the key U.S. market increased.

The higher net profit came on a more than 7% increase in the revenue from operations to Rs. 1,505.6 crore (Rs.1, 401.7 crore).

Commenting on the results, Srinivas Sadu, Executive Chairman of Gland Pharma, said, “We're off to a positive start this year with a growth in revenue and a significant jump in profitability, which was driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships. We're committed to building on this strong foundation, improving our performance, and reinforcing Gland's path toward sustainable growth”

Shyamakant Giri, Chief Executive Officer of Gland Pharma, said, “This quarter’s performance, with improved margins and Cenexi achieving EBITDA break even, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth. At the same time, our continued focus on R&D, adherence to global quality standards, and investment in capability building position us to scale further, tap new markets, and deliver long-term value.”